What's Going On With Aralez Pharmaceuticals?

Shares of Aralez Pharmaceuticals Inc ARLZ, a specialty pharmaceutical company, fell nearly 11 percent on Wednesday ahead of an expected U.S. Food and Drug Administration ruling for its Yosparala therapy.

Aralez's therapy helps prevent cardiovascular disease in patients at-risk for aspirin induced ulcers. Some experts suggested it's "highly likely" Yosprala will be approved by the FDA by the September 14 PDUFA date, which would pave a path towards a commercial launch in the fourth quarter of 2016.

Shares of Aralez were trading lower by more than 12 percent in Thursday's pre-market trading session as no update was provided by the company. However, the stock was halted around 7:10 a.m. ET for pending news.

As of 8:00AM ET there has been no official announcement. Twitter users were mixed on the lack of data as some investors are bracing for potential bad news while others are optimistic.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAMoversGeneralPDUFA DateYosparala
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!